Nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma
Journal of Clinical Oncology Nov 09, 2017
Grosso F et al. -In the current study the efficacy and safety of nintedanib plus chemotherapy for malignant pleural mesothelioma (MPM). It was shown that the addition of nintedanib to pemetrexed plus cisplatin improved the progression-free survival.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
